Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
about
LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouseA novel role for c-Jun N-terminal kinase and phosphoinositide 3-kinase in the liver X receptor-mediated induction of macrophage gene expressionPharmacological manipulations of CNS sirtuins: potential effects on metabolic homeostasis.Polyphenol-rich bilberry ameliorates total cholesterol and LDL-cholesterol when implemented in the diet of Zucker diabetic fatty rats.Purple perilla extracts with α-asarone enhance cholesterol efflux from oxidized LDL-exposed macrophagesRetinoid receptors trigger neuritogenesis in retinal degenerationsAge-dependent therapeutic effects of liver X receptor-α activation in murine polymicrobial sepsis.Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer diseaseTreatment with TO901317, a synthetic liver X receptor agonist, reduces brain damage and attenuates neuroinflammation in experimental intracerebral hemorrhage.Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its associationA big role for small RNAs in HDL homeostasis.Compound K Attenuates the Development of Atherosclerosis in ApoE(-/-) Mice via LXRα ActivationSulfation of 25-hydroxycholesterol regulates lipid metabolism, inflammatory responses, and cell proliferation.Current guidelines for high-density lipoprotein cholesterol in therapy and future directions.Differential scanning calorimetry techniques: applications in biology and nanoscienceSULT2B1: unique properties and characteristics of a hydroxysteroid sulfotransferase family.Biosynthesis of milk fat, protein, and lactose: roles of transcriptional and posttranscriptional regulation.Protein prenylation and human diseases: a balance of protein farnesylation and geranylgeranylation.B-13 progenitor-derived hepatocytes (B-13/H cells) model lipid dysregulation in response to drugs and chemicals.Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes.Predicting selective liver X receptor β agonists using multiple machine learning methods.Contribution of cholesterol and oxysterols in the physiopathology of cataract: implication for the development of pharmacological treatmentsLiver X receptor and peroxisome proliferator-activated receptor agonist from Cornus alternifolia.Liver X receptor agonist inhibits HIV-1 replication and prevents HIV-induced reduction of plasma HDL in humanized mouse model of HIV infection.Liver X receptor activation increases hepatic fatty acid desaturation by the induction of SCD1 expression through an LXRα-SREBP1c-dependent mechanism.Liver X Receptor Agonist Therapy Prevents Diffuse Alveolar Hemorrhage in Murine Lupus by Repolarizing Macrophages.Liraglutide protects cardiac function in diabetic rats through the PPARα pathway.Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet.LXRβ activation increases intestinal cholesterol absorption, leading to an atherogenic lipoprotein profile.Oxysterols Increase Inflammation, Lipid Marker Levels and Reflect Accelerated Endothelial Dysfunction in Experimental Animals.
P2860
Q30491802-C9BBF042-8C64-4771-9F08-25063EE9F527Q33744653-52573289-1A69-4E7A-A6EF-34530C39F5FDQ33857250-1FD6C6DF-7E8C-4A59-9BC4-272C7D28B6FFQ34159251-DC20F69F-35A6-40B0-A762-472C0CD1CF8BQ35167931-D98C5939-87DC-4672-9D07-DB83947AE65FQ35648032-C98CDE3B-D549-44FE-8991-F60E77DFC913Q35875675-71F73B9A-C6AB-456B-932A-0EB3C686EFC9Q36419283-BF34ED28-0564-4D3C-8600-90316F360797Q36478244-C238A815-B98B-42DA-91F0-626E606F331BQ36679163-41C241A9-B31B-4A6C-8F18-6FBCBCE8DDF2Q36694632-9532B132-6DA1-4CB0-A600-680B626475EAQ36754770-D3C0ABA2-72CE-4398-A814-D94B5031D668Q37134445-1A1EEE78-C6E5-4804-9A0A-A8733710903BQ37575402-1E8603DE-0C8C-45F6-A9A6-F9138BB13065Q37702199-21B6D3EC-F6DA-44C8-82B7-D0DBB84D409CQ37814131-035EEC09-64B2-4309-AF2E-181EEDC565B0Q38135858-6BAF5546-2A9A-4D5A-9923-A8186FB26150Q38294157-EFBBDE0E-3340-4197-84AF-B9514ABBB117Q38415670-62CA4F14-A2D8-42FA-B3BC-DE3B63283D1DQ38702009-CB988F00-22CB-4C3D-9370-B42B725FC5B3Q38741861-7E7F9CD0-ACA4-4CC6-80C4-3E9FD45DB869Q38965138-CC277180-F6B1-4F55-954B-D3BFC0F31D3AQ41312416-6326C102-F63E-40FF-9470-639B2E23BF3BQ41879279-2C8B0194-E6DB-499D-BA15-69850EE00AE8Q42174181-14C20588-1B2A-4CAF-B55C-28C996B8417CQ42602737-11ECE917-F127-492B-A102-1902F899573FQ46960260-8C438D6F-1126-4E75-AB10-5472BECC4396Q49884890-67584A2B-2578-48E6-B86F-DDFEFDBF87B3Q50026330-35457716-0BD0-4E77-987B-23212A47EB6CQ50490456-82CB684E-51CF-4B5E-BEFE-7050BE96A239Q54324443-1812AACA-753C-42C8-9CC5-15E496974CB4Q55364950-79EE528A-CF5E-48C9-9B90-1A1737F522FF
P2860
Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
@ast
Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
@en
type
label
Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
@ast
Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
@en
prefLabel
Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
@ast
Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
@en
P1476
Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
@en
P2093
Jerzy Bełtowski
P304
P356
10.1111/J.1755-5922.2008.00062.X
P577
2008-01-01T00:00:00Z